The negative correlation between m5C scores and PD-L1 expression, alongside a positive association with tumor mutation burden (TMB), underscores the potential of combining epigenetic therapies with immune checkpoint inhibitors to improve immunotherapy responses in cervical cancer [110]. The gene discussed is CD274; the disease is cervical carcinoma.